Concurrent Investment Advisors LLC bought a new position in shares of Relx Plc (NYSE:RELX - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 9,877 shares of the technology company's stock, valued at approximately $498,000.
A number of other large investors also recently modified their holdings of RELX. Golden State Wealth Management LLC increased its holdings in Relx by 100.0% during the 1st quarter. Golden State Wealth Management LLC now owns 588 shares of the technology company's stock worth $30,000 after acquiring an additional 294 shares during the period. Transce3nd LLC bought a new position in shares of Relx in the fourth quarter worth $40,000. Brown Brothers Harriman & Co. raised its position in shares of Relx by 218.5% in the fourth quarter. Brown Brothers Harriman & Co. now owns 965 shares of the technology company's stock worth $44,000 after buying an additional 662 shares in the last quarter. Redwood Investments LLC bought a new stake in Relx during the fourth quarter valued at $120,000. Finally, Steward Partners Investment Advisory LLC grew its position in Relx by 50.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,751 shares of the technology company's stock worth $125,000 after buying an additional 919 shares in the last quarter. 15.02% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on RELX. Morgan Stanley reiterated an "overweight" rating on shares of Relx in a research report on Wednesday, April 16th. Barclays upgraded shares of Relx from an "equal weight" rating to an "overweight" rating in a research report on Friday, March 14th. Wall Street Zen lowered shares of Relx from a "buy" rating to a "hold" rating in a report on Saturday. Finally, The Goldman Sachs Group began coverage on shares of Relx in a report on Wednesday, March 26th. They set a "buy" rating for the company. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Relx currently has a consensus rating of "Buy".
View Our Latest Stock Report on RELX
Relx Trading Down 1.1%
Shares of Relx stock traded down $0.58 during trading on Friday, reaching $53.61. The company's stock had a trading volume of 1,234,307 shares, compared to its average volume of 747,697. The company has a quick ratio of 0.47, a current ratio of 0.52 and a debt-to-equity ratio of 1.46. Relx Plc has a 52-week low of $43.45 and a 52-week high of $56.33. The firm's 50-day moving average is $53.77 and its two-hundred day moving average is $50.82. The company has a market cap of $100.67 billion, a price-to-earnings ratio of 28.82, a PEG ratio of 3.26 and a beta of 0.83.
Relx Profile
(
Free Report)
RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.
Featured Articles

Before you consider RELX, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RELX wasn't on the list.
While RELX currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.